Vitae Pharma Q4 and FY14 results Vitae Pharmaceuticals (VTAE +0.9%) Q4 results: Revenues: $0.2M (-98.7%); R&D Expense: $5.1M (+34.2%); SG&A: $2.2M (+57.1%); Operating Loss: ($7.1M) (-171.0%); Net Loss: ($7.3M) (-175.3%); Loss Per Share: ($0.40) (-154.1%). FY2014 results: Revenues: $8.7M (-61.3%); R&D Expense: $19.3M (+29.5%); SG&A: $7.9M (+46.3%); Operating Loss: ($18.5M) (-940.9%); Net Loss: ($19.1M) (-999%); Loss Per Share: ($3.61); Quick Assets: $65.3M (+100.9%).